Please use this identifier to cite or link to this item: https://dspace.iiti.ac.in/handle/123456789/3856
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJakhmola, Shwetaen_US
dc.contributor.authorIndari, Omkaren_US
dc.contributor.authorJha, Hem Chandraen_US
dc.date.accessioned2022-03-17T01:00:00Z-
dc.date.accessioned2022-03-17T15:30:51Z-
dc.date.available2022-03-17T01:00:00Z-
dc.date.available2022-03-17T15:30:51Z-
dc.date.issued2021-
dc.identifier.citationAnand, U., Jakhmola, S., Indari, O., Jha, H. C., Chen, Z. -., Tripathi, V., & Pérez de la Lastra, J. M. (2021). Potential therapeutic targets and vaccine development for SARS-CoV-2/COVID-19 pandemic management: A review on the recent update. Frontiers in Immunology, 12 doi:10.3389/fimmu.2021.658519en_US
dc.identifier.issn1664-3224-
dc.identifier.otherEID(2-s2.0-85110120018)-
dc.identifier.urihttps://doi.org/10.3389/fimmu.2021.658519-
dc.identifier.urihttps://dspace.iiti.ac.in/handle/123456789/3856-
dc.description.abstractSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19. © Copyright © 2021 Anand, Jakhmola, Indari, Jha, Chen, Tripathi and Pérez de la Lastra.en_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.sourceFrontiers in Immunologyen_US
dc.subjectacicloviren_US
dc.subjectad26.cov2.s vaccineen_US
dc.subjectalanine aminotransferaseen_US
dc.subjectamphiregulinen_US
dc.subjectangiotensin converting enzyme 2en_US
dc.subjectbaricitiniben_US
dc.subjectc c motif chemokine ligand 3 like 1en_US
dc.subjectC reactive proteinen_US
dc.subjectcathelicidinen_US
dc.subjectcorticosteroiden_US
dc.subjectcreatine kinaseen_US
dc.subjectcreatinineen_US
dc.subjectCXCL1 chemokineen_US
dc.subjectCXCL2 chemokineen_US
dc.subjectdapivirineen_US
dc.subjectdefensinen_US
dc.subjectefavirenzen_US
dc.subjectepinephrineen_US
dc.subjectferritinen_US
dc.subjectheparinen_US
dc.subjectinflammasomeen_US
dc.subjectinfluenza vaccineen_US
dc.subjectinterleukin 18en_US
dc.subjectinterleukin 1betaen_US
dc.subjectivermectinen_US
dc.subjectJanus kinase inhibitoren_US
dc.subjectlactate dehydrogenaseen_US
dc.subjectlopinaviren_US
dc.subjectmicrosomal aminopeptidaseen_US
dc.subjectmonoclonal antibodyen_US
dc.subjectnanobodyen_US
dc.subjectnelfinaviren_US
dc.subjectneuropilin 1en_US
dc.subjectneutralizing antibodyen_US
dc.subjectnitazoxanideen_US
dc.subjectnucleocapsid proteinen_US
dc.subjectopen reading frame 8en_US
dc.subjectpattern recognition receptoren_US
dc.subjectprocalcitoninen_US
dc.subjectreceptor binding domainen_US
dc.subjectribavirinen_US
dc.subjectritonaviren_US
dc.subjectRNA directed RNA polymeraseen_US
dc.subjectSARS-CoV-2 vaccineen_US
dc.subjectsmall interfering RNAen_US
dc.subjecttnf superfamily member 10en_US
dc.subjecttoll like receptor 3en_US
dc.subjecttoll like receptor 7en_US
dc.subjecttoll like receptor 8en_US
dc.subjecttoll like receptor 9en_US
dc.subjecttroponinen_US
dc.subjecttroponin Ien_US
dc.subjecttumor necrosis factoren_US
dc.subjectunclassified drugen_US
dc.subjectviral proteinen_US
dc.subjectzidovudineen_US
dc.subjectantivirus agenten_US
dc.subjectDNA vaccineen_US
dc.subjectinactivated vaccineen_US
dc.subjectvirus antibodyen_US
dc.subjectadult respiratory distress syndromeen_US
dc.subjectantibody responseen_US
dc.subjectantigen presenting cellen_US
dc.subjectartificial ventilationen_US
dc.subjectbioinformaticsen_US
dc.subjectCD4+ T lymphocyteen_US
dc.subjectCD8+ T lymphocyteen_US
dc.subjectcerebral sinus thrombosisen_US
dc.subjectcoronavirus disease 2019en_US
dc.subjectcytotoxicityen_US
dc.subjectdisease transmissionen_US
dc.subjectdrug repositioningen_US
dc.subjecthospitalizationen_US
dc.subjecthumanen_US
dc.subjectHuman immunodeficiency virusen_US
dc.subjectHuman immunodeficiency virus infectionen_US
dc.subjectHuman respiratory syncytial virusen_US
dc.subjectimmune responseen_US
dc.subjectimmunizationen_US
dc.subjectinfluenzaen_US
dc.subjectInfluenza virusen_US
dc.subjectMiddle East respiratory syndromeen_US
dc.subjectMiddle East respiratory syndrome coronavirusen_US
dc.subjectmultiple organ failureen_US
dc.subjectnerve cell plasticityen_US
dc.subjectoxygen therapyen_US
dc.subjectpandemicen_US
dc.subjectperipheral blood mononuclear cellen_US
dc.subjectprevalenceen_US
dc.subjectprotein expressionen_US
dc.subjectrespiratory tract diseaseen_US
dc.subjectReviewen_US
dc.subjectRNA interferenceen_US
dc.subjectSARS coronavirusen_US
dc.subjectTh17 cellen_US
dc.subjectvirus loaden_US
dc.subjectvirus replicationen_US
dc.subjectvirus transmissionen_US
dc.subjectdrug therapyen_US
dc.subjectepidemiologyen_US
dc.subjectgeneticsen_US
dc.subjectimmunityen_US
dc.subjectimmunologyen_US
dc.subjectmolecular libraryen_US
dc.subjectmutation rateen_US
dc.subjectpandemicen_US
dc.subjectprevention and controlen_US
dc.subjectAntibodies, Viralen_US
dc.subjectAntiviral Agentsen_US
dc.subjectCOVID-19en_US
dc.subjectCOVID-19 Vaccinesen_US
dc.subjectHost Microbial Interactionsen_US
dc.subjectHumansen_US
dc.subjectImmunityen_US
dc.subjectMutation Rateen_US
dc.subjectPandemicsen_US
dc.subjectSARS-CoV-2en_US
dc.subjectSmall Molecule Librariesen_US
dc.subjectVaccines, DNAen_US
dc.subjectVaccines, Inactivateden_US
dc.titlePotential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Updateen_US
dc.typeReviewen_US
dc.rights.licenseAll Open Access, Gold, Green-
Appears in Collections:Department of Biosciences and Biomedical Engineering

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetric Badge: